# Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Source: https://onco.cc/trials/nct05379985/  
OnCo record `nct05379985` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Daraxonrasib in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.

## Summary

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS is a phase 1/2 interventional study registered as NCT05379985 by Revolution Medicines, Inc., with 754 participants planned, started 2022-05-31 and due to reach its primary completion in 2027-05-31. Interventions recorded: RMC-6236. Conditions listed: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05379985
- Phase: 1/2
- Setting: A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 754

## Sources

- ClinicalTrials.gov NCT05379985: https://clinicaltrials.gov/study/NCT05379985

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct05379985.json